Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

You may be eligible if

• Histologically confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following:
• 1. Follicular lymphoma (FL) Grade 1, 2, or 3a
• 2. Small lymphocytic lymphoma (SLL) with absolute lymphocyte count \< 5 x 10\^9/L at the time of diagnosis
• 3. Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)
• 4. Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)
• Ongoing drug-induced liver injury, active hepatitis C, active hepatitis B , alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
• Received previous treatment with rituximab that was not effective.